Skip to main content

Ad19a/64 Adenoviral Vector

Ad19a/64 vector for vaccination

Our proprietary Ad19a/64 vector (Subtype D) can be used to overcome the low transduction efficiency of commonly used Ad serotypes and help overcome the challenge of pre-existing immunity. It is an attractive alternative for the most commonly used human adenovirus type 5 (Ad5) for specific types of applications.

Ad19a/64 is the first accessible subtype D adenovirus vector. This vector provides superior transduction of human cells (e.g., dendritic cells, cardiomyocytes, fibroblasts, PBMCs, myoblasts, and myotubes) when compared to Ad5. It also possesses CAR-independent binding properties, targeting sialic acid-dependent receptors. In preclinical vaccine studies, the vector induced superior levels of CD4 and CD8 immune responses in non-human primates.

Key benefits of our Ad19a/64 vector
Transduction experiments with human myoblasts and primary myotubes
Ad19a/64 in mucosal boost immunization against SARS-CoV-2
Licensing information

Questions?
We’re here to help.

Contact us

Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.